malignancy, are managed. Some patients are referred to liver clinic due to elevated fibrosis scores as a result of other pathologies, and the enhanced liver fibrosis (ELF) test has recently been added to our algorithm to further stratify those who require liver services.

**PWE-8** ALBUMIN BILIRUBIN SCORE FOR PREDICTING MORTALITY IN SUDANESE PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE

1Esraa Barri*, 2Omer Kheir, 3Salma Barakat. 1Hepatology unit, NCGLO, Khartoum, Sudan; 2Research unit, NCGLD, Khartoum, Sudan

Abstract PWE-8 Figure 1 The multiple receiver operating characteristic curve (ROC) to evaluate validity of MELD, ALBI and CTP in detecting the 28-days mortality

**Introduction** The albumin-bilirubin (ALBI) score, a new model for assessing severity of liver dysfunction was initially used in hepatocellular carcinoma but has not been thoroughly investigated in ACLF. The aim of this study was to assess prognostic value of ALBI score for predicting 28 days mortality in Sudanese patients with ACLF.

**Methods** This cross-sectional study included 34 patients diagnosed as ACLF using APASL criteria for diagnosis. The etiology of the underlying chronic liver disease and precipitating cause of ACLF were investigated and ALBI, MELD and CTP scores were calculated within 24 hours of admission. Mortality was assessed during hospital stay and if discharged at 28 days post enrollment by telephone conversation. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS 2.0).

**Results** ALBI scores were significantly associated with 28-days outcome as the mean of ALBI in the non-survived patients was higher than in the survived (-0.45±0.39 vs -0.65±0.59; P value = 0.004). Regarding the predictive performances of the ALBI, MELD and CTP scores in detecting the 28-days mortality, ROC analysis showed that the AUC of MELD was 0.746 (95% CI: 0.575-0.916; P value = 0.015), ALBI was 0.700 (95% CI: 0.512-0.888; P value = 0.048), and CTP was 0.533 (95% CI: 0.334-0.733; P value = 0.742).

**Conclusion** A higher ALBI score measured at admission is a useful predictor of 28 day mortality in ACLF patients. ALBI score was comparable to MELD and did better than CTP scores in predicting short-term mortality in these patients.

**PWE-9** MISSED OPPORTUNITIES FOR EFFECTIVE ALCOHOL SCREENING IN THE EMERGENCY DEPARTMENT – TIME TO ACT?

Neil Gordon*, Jill Harrison, Rebecca Fennell, Dianne Backhouse, George Abouda, Lynsey Corless. Hull University Teaching Hospitals NHS Trust, Hull, UK

**Introduction** Alcohol Care Teams (ACT) are integral to best-practice management of people with Alcohol Use Disorders (AUD), the consequences of which represent a significant proportion of in-patient hepatology activity in the UK. The ACT in our centre was established in January 2020. It comprises two clinical nurse specialists (CNS) providing comprehensive alcohol assessments and psychological interventions, supervised medical withdrawal and fibrosis screening, and a community-led, hospital-based addiction counselling service (ReNew), and is supported by 2 consultants. The CNS service is funded to provide only weekday cover (8am - 5pm) and there is currently no formal alcohol screening process in the Emergency Department (ED), potentially leading to missed opportunities for intervention. We therefore performed an audit to determine effectiveness of AUD screening in ED.

**Methods** A retrospective analysis of all ED attendances from 6/6/20 to 6/9/20 was undertaken. Visits coded with a diagnosis wholly attributable to alcohol were identified as opportunities for AUD screening. Records were reviewed for presence/absence of AUD screening (specifically scores such as AUDIT), and if a referral was made to ACT. Data was also collected on how many attendances resulted in hospital admission, and if ACT CNS review took place at any time during that period. A secondary analysis was performed looking specifically at frequent attenders (patients who had attended ED >10 times in 12 months).

**Results** 462 unique attendances (326 patients) were recorded, with ‘Intoxicated’ the most frequent reason coded. Only 8 attendances (1.7%) were referred to ACT, and just 1 (0.2%) had documented evidence of formal alcohol screening. 365 (79%) of attendances were at weekends/out-of-hours, most of which is not covered by current ACT funding, and this may partly explain the very low referral rates. There were 175 (38%) admissions to a medical or short stay area. Of those, 55 (31%) were seen by ACT. Repeat attendances were common: 26 patients had attended ED >10 times in the last year (mean=19/patient) and worryingly, 46% of those had never been reviewed by ACT CNS. 35% of patients who did receive ACT input for medically-assisted withdrawal remained abstinent at 1 month, suggesting considerable potential to improve abstinence rates across our population by increasing ACT referrals.

**Conclusions** This audit illustrates the consequences of inadequate AUD screening in ED, and subsequent lost opportunities to signpost the majority who do not require admission, to community alcohol services; namely high rates of hospital admissions, frequent attendances, and greater numbers of...
patients with ongoing alcohol dependence. Extending ACT CNS support across 7 days and deployment of an Assertive Outreach Service should both be considered.

**PWE-10** LIVER TRANSPLANT OUTREACH SERVICE: ASSESSMENT OF OUTCOMES SEPT 2019-DEC 2020

1Rebecca Jones*, 1L Burke, 1M Prince, 1C Lane, 1C Rouke, 2V Heslop, 2RL Jones. 1Manchester University NHS Foundation Trust, Manchester, UK; 2Leeds Teaching Hospitals NHS Trust, Leeds, UK

Introduction Distance from a transplant centre may present a barrier to liver transplant referrals and transplant recipients report disliking travel for long-term follow-up. A liver transplant outreach service based at Manchester Royal Infirmary (MRI) was established collaboratively between the MRI and a transplant centre in Sept 2019. We report the outcomes from this service.

Methods The service runs one day/month and includes post-transplant reviews, transplant assessment triage clinic and a ‘working lunch’ complex case meeting. Baseline transplant assessment + listing data between April 2017- March 2019 for chronic liver disease indications were collected and compared with those between Sept 2019-Dec 2020, in addition to other service activity data.

Results In the 24 month period in 2017-19 there were 11 chronic liver disease (CLD), excluding HCC, transplant assessments from the MRI. Only 8 were assessed as outpatients. Median referral UKELD was 56, 7/11 were listed with an assessment:listing conversion of 63%.

In the 15 month period Sept 2019-Dec 2019 there were 27 pre-transplant reviews with 20 new patients, 4 with HCC and 16 with CLD. One CLD patient had associated HCC. The most common liver disease indication for review was alcohol related in 8 patients. Nineteen (90%) patients were reviewed for transplant assessment suitability. 12 (63%) were referred for assessment with investigations done locally. 9 (75%) were for chronic liver disease indications and 3 (25%) were for HCC. Median UKELD was 53.5.

9 assessments have been completed, with 8 wait-listed. None were converted to inpatient assessments. Overall assessment:listing conversion is high: 8/9(88.8%) overall. 3 transplanted to date. 2 HCC patients had bridging therapies locally.

Of 7 not referred for assessment, 1 was suitable for a TIPSS locally, 1 needed pre-habilitation and is under follow-up. 1 was out-with HCC criteria + is managed locally (still alive). 3 were too advanced/frail + all have since died. 1 was initially thought suitable for assessment but did not progress due to alcohol relapse. During the period April 20-Aug 20 only 1 pre-transplant patient was referred as NHS services were curtailed due to the Covid-19 pandemic.

112 post-transplant reviews have been delivered, in 82 recipients. 98% gave positive feedback. Post-transplant interventions delivered locally include 2 liver biopsies, 1venogram + the management of 1patient with acute rejection.

Conclusion Despite the pandemic this service provided improved pre-transplant outcomes in a shorter time frame cf. the preceding 2 years and saved 139 appointments in the transplant centre. The service is efficient, popular with patients, and adds to the case for the widespread adoption of similar partnerships within liver transplant networks.

**PWE-11** CAN THE ONLINE SHOPPING MODEL ‘LOCK-BOX DELIVERY’ IMPROVE HEPATITIS C TREATMENT ACCESS AMONGST VULNERABLE ADULTS?

1Fiona Rees*, 1Anja St Clair Jones, 1Margaret O’Sullivan, 1,2Sumita Verma. 1Brighton and Sussex University Hospitals Trust, Brighton, UK; 2Brighton and Sussex Medical School, Brighton, UK

Introduction Hepatitis C virus (HCV) predominantly affects vulnerable and disenfranchised individuals, including people who use drugs (PWUD) and people who are homeless (PWAH); our prior work shows only 5% attend hospital appointments for HCV management.

Methods The medication homecare delivery model has been used successfully within our Sussex Hepatology Operational Delivery Network (ODN) but relies on clients having an address and/or the ability to sign for deliveries; the latter also proves difficult in hostels where hostel staff are reluctant to be involved with medication deliveries.

On-line shopping companies have adopted ‘lock-box’ delivery systems for customers who are unable to sign for a delivery, storing the parcel in a secure lock-box thus enabling later convenient collection. We adopted this strategy to ensure safe provision of HCV medications for difficult-to-engage individuals.

Lock-boxes were installed in two centrally located Brighton hostels that were participating in our on-going community-based studies; a day hostel (which is accessed by PWUD and PWAH so providing a convenient collection point for these clients) and a residential hostel (which houses PWAH). Lock-boxes at the residential hostel enables micro-elimination within the hostel. Access to lock-boxes was via client-specific key-codes with override facilities available for the pilot leads.

Once clients were assessed to be eligible for HCV treatment at the weekly multi-disciplinary ODN meeting, the pharmacy team prescribed and managed delivery to the lock-boxes. Prescribing was enabled via non-medical prescribing pharmacists, cost effective dispensing was guaranteed using the outsourced outpatient pharmacy, medication was dispensed in weekly or monthly blister-packs (depending on client requirements via HCV nurse assessment) and deliveries completed monthly. Usage was monitored on a continuous basis when refilling the lock-boxes and via close relationship with the treating HCV nurse.

Results This pilot ran from January 2020 to April 2020. Seven clients were entered into the pilot. Two PWUD/PWAH and four hostel-resident clients successfully completed HCV treatment. One client decided to disengage from treatment unrelated to the lock-box. The feedback has been overwhelmingly positive from both clients and service providers. The pilot was reliant on one specialised ODN pharmacist. Unfortunately, due to COVID-19 this pilot was put on hold but aims to continue once COVID-19 risks are manageable.

Conclusions Preliminary results from this innovative pilot are favourable as regards improving access to HCV treatment amongst a difficult-to-engage cohort and merits further assessment.